Next-Gen Anticoagulant Lands FDA Nod for Secondary Stroke Prevention
(MedPage Today) -- The FDA approved asundexian (Sunharbo) as the first factor XIa (FXIa) inhibitor for secondary stroke prevention, the agency announced on Monday. Asundexian, an oral, direct, small-molecule inhibitor of FXIa, is indicated for...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.